Board of Directors
At present, the Board of Directors is composed of five members. The Board members’ business address is Exiqon A/S, Skelstedet 16, DK-2950 Vedbæk, Denmark.
A list of the members of the Board of Directors is set out below.
Thorleif Krarup, Chairman
(born 1952, Danish citizen). Thorleif Krarup holds a number of directorships and is Senior Advisor to Nordic Capital. Throughout the past 20 years, Thorleif Krarup has served as Managing Director/Group CEO in Nykredit (1985-1992), Unibank (1992-2000) and Nordea (2000-2003).
Per Wold-Olsen, Board member
(born 1947, Norwegian citizen) MBA, started his 30 years with Merck in 1976. In 1991 he was appointed Senior Vice President, Worldwide Human Health Marketing, in 1994 President Human Health - Europe, and in 1997 he also assumed responsibility for Central & Eastern Europe, the Middle East and Africa. Recently appointed chariman of H. Lundbeck A/S. Frank J. Kiesner, Board member
(born 1944, U.S. citizen) Frank J. Kiesner, J.D. was President and CEO of Oncotech from 1992 until 2008. Frank J. Kiesner has served on the Board of the University ogf California, Irvine (UCI) Foundation and the Board of Directors of the College of Biomedical Engineering at UCI. He was Chairman of the Directors Council for the UCI Cancer Center, as well as serving on the board of numerous civic groups.
Michael Nobel, Board member
(born 1956, Danish citizen) Trained and employed with A.P.Møller between 1978 and 1983, after which time he became Export Manager with E. Nobel Cigar og Tobaksfabrikker A/S and Skandinavisk Tobakskompagni A/S. Michael Nobel is co-founder and chairman of the software company Medtime A/S
Erik Walldén, Vice Chairman
(born 1949, Swedish citizen).Erik Walldén has worked in the biotech industry for many years and had managerial positions in marketing with Pharmacia LKB Biotechnology AB and PerSeptive Biosystems. Erik Walldén is former CEO of Pyrosequencing and Biacore AB, and was recently appopinted CEO of Affibody.
Management
The Executive Management is responsible for the day-today management of the Company.
| 
| Lars Kongsbak, Chief Executive Officer
(born 1961, Danish citizen,), M.Sc. in Biology from the University of Copenhagen (1988), PhD in Molecular Biology from the Technical University of Denmark (1990), joined Exiqon in 2000 as head of the EURAY division, later of R&D and fi nally in charge of Business Development, before he was appointed as CEO in 2003. Lars Kongsbak is the only member of the Executive Management who is registered as an executive director with the Danish Commerce and Companies Agency. Before joining Exiqon, Lars Kongsbak served as Senior Scientist with Novozymes, Novo Nordisk and Bioimage, respectively. For several years, Lars Kongsbak was a Post Doc in the United States, Australia and Denmark. Lars Kongsbak is the inventor of several patents and the author of more than 40 scientific publications.
|
|
| Hans Henrik Chrois Christensen, Chief Financial Officer
(born 1965, Danish citizen), LLM from the University of Copenhagen (1990) and attorney-at-law (1993) with a right to appear before the Danish High Court, joined Exiqon as CFO on 1 January 2007 from a corresponding position with Pharmexa A/S, where he was employed in 2002 and had various areas of responsibility before being appointed as CFO in 2004. Hans Henrik Chrois Christensen has a background as a group general counsel with Danisco A/S (1998-2002) where he completed an in-house management training programme and worked with research and licence collaborations, joint ventures and venture investments and as an attorney at-law with the law firm Dragsted & Helmer Nielsen (now Bech-Bruun) Copenhagen (1990-1998).
|
|
| Michael Kallelis, General Manager, Exiqon Inc
(born 1958, US citizen,), B.Sc. in Biology/Chemistry, joined Exiqon Inc. in January 2006. Michael Kallelis has more than 25 years of experience within Life Science, including mergers, acquisitions, liquidation, strategic planning, ISO certifi cation, FDA inspections, GMP functions, capital utilisation projects, business development, licensing, research and development contracts and board work. Michael Kallelis previously held the position of Vice President, Chemistry, Production and Control in Achemix (2005-2006), a US pharmaceutical company, and before that he served as Chief Operating Officer and Executive Vice President in the company Avecia Biotechnology, Inc. (1999-2004), a UK biotech company.
|
|
| Peter Stein Nielsen, Vice President in charge of Production
(born 1961, Danish citizen) M.Sc. in Biology (1987), PhD in Natural Science (1991). Was a Post Doc at the Norwegian University of Life Sciences in Ås until 1995. Thereafter employed as a research lecturer with the Technical University of Denmark (1996-1999) and subsequently at Carlsberg Laboratory (1999-2001). Joined Exiqon in 2001 as Senior Research Scientist and was appointed as Senior Principal Scientist in 2005. In 2006 he was appointed as Vice President, Production. Peter Stein Nielsen is the inventor of several patents and the author of numerous scientific publications.
|
|
| Søren Morgenthaler Echwald, Vice President in charge of Business Development
(born 1967, Danish citizen), M.Sc. in Chemistry & Genetics (1993), PhD (1998), joined Exiqon in 2001. He was promoted to Senior Manager, Business Development in 2003, and since 2006 he has served as Vice President in charge of Business Development, including licensing, patent strategy and market research. Søren Morgenthaler Echwald previously held a position of Senior Scientist with Steno Diabetes Center (Novo Nordisk A/S) focusing on the development of gene diagnostics within obesity and diabetes, and he has co-authored more than 50 scientific articles.
|
|
| Mette Flansmose, Vice President, Project Management and Process Control
(born 1971, Danish citizen). B.Sc. (chemical engineering) (1994). Held a position withNovozymes from 1994 to 1998 in production and from 1998 to 2001 she was part of Novozyme’s Quality Management. Mette Flansmose served as Project Manager with Novozymes R&D in 2001 and moved on to become Senior Project Manager from 2001 to 2005. Between 2005 and 2007, Mette Flansmose was Vice President, Project management in CMC Biopharmaceuticals A/S. She joined Exiqon in 2007 as Vice President, Project Management and Process Control.
|
|
| Søren Møller, Chief Scientific Officer & Vice President of Research & Development
(born 1967, Danish citizen, M.Sc. in Engineering (1993), PhD in Molecular Biology (1997), was a Post Doc at Stanford University until 1998. Employed as a researcher with NovoNordisk/ Novozymes in 1988 and employed with Exiqon in 2001 as Senior Manager, Business Development. Between 2003 and 2005, Søren Møller was employed with BioImage A/S in various managerial positions and was part of the company’s Business Development team, among other things. In 2005, he joined Exiqon again as Vice President of Research & Development. Søren Møller is the inventor of several patents and the author of numerous scientific publications.
|
|
| Henrik Pfundheller, Vice President, Sales & Marketing
(born 1971, Danish citizen), M.Sc. in Chemistry and Biology (1997), PhD (1999), EBA (2004), joined Exiqon in 1999 as Senior Scientist and following a short period of employment with NeuroSearch as Medical Scientist (2000) joined Exiqon again as Manager of Chemistry. In 2002, he was appointed Director of Chemistry & Process Technology. In 2004 he was assigned to set up Exiqon’s Sales & Marketing division, and in 2006 he was appointed Vice President, Sales & Marketing. Inventor of several patents and author of numerous scientific publications. |
|
| |
|
